Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06566547
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-20
Brief Title:
GR1803 Injection in Patients With RelapsedRefractory Multiple Myeloma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Single-Arm Open Multi-Center Phase II Clinical Trial of the Efficacy Safety Pharmacokinetics and Immunogenicity of GR1803 Injection in Patients With RelapsedRefractory Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs except in cases of disease progression due to discontinuation of the drug as a result of an adverse event or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None